Biotinylated Mouse Fc gamma RIIB / CD32b Protein, Avitag™,His Tag (SPR & BLI verified)
Proteins and Peptides
- 貨號 Cat. No.
- CDB-M82E8
- 規格 Size
- 25ug
- 品牌 Brand
- ACROBiosystems
- Species
- Mouse
- Conjugate
- Precision Avi
- Expression System
- HEK293
- Tag
- Avi Tag 、 His Tag
Description
Source :
Biotinylated Mouse CD32b, Avitag,His Tag (SPR & BLI verified) (CDB-M82E8) is expressed from human 293 cells (HEK293). It contains AA Thr 40 - Arg 217 (Accession # NP_001070657.1).
Molecule : Fc gamma RIIB / CD32b
Synonyms : FCGR2B,CD32b,CD32,FCG2,IGFR2,CDw32
Format : Powder
Category : MABSol® Biotin Labeled Proteins
Accession : NP_001070657.1
Storage : -20℃
Shipping condition : Powder,RT
Molecular Weight : 24.0 kDa
Characteristics :
This protein carries an Avi tag (Avitag™) at the C-terminus, followed by a polyhistidine tag. The protein has a calculated MW of 24.0 kDa. The protein migrates as 38-45 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.
Endotoxin Level : Less than 1.0 EU per μg by the LAL method.
Buffer : PBS, pH7.4
Description :
Receptors for the Fc region of IgG (Fc γ R) are members of the Ig superfamily that function in the activation or inhibition of immune responses. Three classes of human Fc γ Rs: RI (CD64), RII (CD32), and RIII (CD16), which generate multiple isoforms, are recognized.
There are three genes for human Fcγ RII /CD32 (A, B, and C) and one for mouse Fcγ RII B (CD32B). CD32 is a low affinity receptor for IgG. Low affinity immunoglobulin gamma Fc region receptor II-b (FCGR2B) is also known as CD32b, FCG2, IGFR2. CD32B is expressed on B cells and myeloid dendritic cells. Ligation of CD32B on B cells downregulates antibody production and may, in some circumstances, promote apoptosis. Co-ligation of CD32B on dendritic cells inhibits maturation and blocks cell activation. CD32B may also be a target for monoclonal antibody therapy for malignancies.
References :
(1) Hamada F., et al., 1993, Proc. Natl. Acad. Sci. U.S.A. 90:6305-6309.
(2) Sarmay G., et al., 1997, Immunol. Lett. 57:159-164.
(3) Laine D., et al., 2005, J. Gen. Virol. 86:1771-1784.

